128 related articles for article (PubMed ID: 37668391)
21. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
[TBL] [Abstract][Full Text] [Related]
22. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
24. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
[TBL] [Abstract][Full Text] [Related]
25. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
26. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
27. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
[TBL] [Abstract][Full Text] [Related]
28. The role of lymphadenectomy in patients with stage III&IV uterine serous carcinoma: Results of multicentric Turkish study.
Cakir C; Kilic F; Kilic C; Tokgozoglu N; Ersak B; Ayhan S; Akar S; Yuksel D; Korkmaz V; Boran N; Toptas T; Kimyon Comert G; Ureyen I; Tasci T; Turkmen O; Moraloglu Tekin O; Ustun Y; Turan T
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):102063. PubMed ID: 33453448
[TBL] [Abstract][Full Text] [Related]
29. Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery.
Hosono S; Kajiyama H; Mizuno K; Sakakibara K; Matsuzawa K; Takeda A; Kawai M; Nagasaka T; Kikkawa F
Int J Clin Oncol; 2011 Oct; 16(5):524-32. PubMed ID: 21431342
[TBL] [Abstract][Full Text] [Related]
30. Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.
Nasioudis D; Mastroyannis SA; Ko EM; Haggerty AF; Cory L; Giuntoli RL; Kim SH; Morgan MA; Latif NA
Gynecol Oncol; 2022 Aug; 166(2):263-268. PubMed ID: 35667901
[TBL] [Abstract][Full Text] [Related]
31. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Shaalan W; Elemam D; Mansour H; Melis M; Malik E; Soliman AA
J Gynecol Oncol; 2018 Jul; 29(4):e47. PubMed ID: 29770618
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
[TBL] [Abstract][Full Text] [Related]
33. [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
Tang L; Zheng M; Xiong Y; Ding H; Liu FY
Ai Zheng; 2008 Sep; 27(9):951-5. PubMed ID: 18799034
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant Chemotherapy May Not Be Necessary for Women with Stage IC1 Epithelial Ovarian Cancer.
Deng DM; Liao QY; Yang J; Chen J; Chen G; Bai HL; Zhang B; Li KZ
Curr Med Sci; 2022 Feb; 42(1):192-200. PubMed ID: 34755262
[TBL] [Abstract][Full Text] [Related]
35. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
Gynecol Oncol; 2016 Dec; 143(3):490-495. PubMed ID: 27771168
[TBL] [Abstract][Full Text] [Related]
36. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
[TBL] [Abstract][Full Text] [Related]
37. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
Smoter M; Bodnar L; Grala B; Stec R; Zieniuk K; Kozlowski W; Szczylik C
J Exp Clin Cancer Res; 2013 Apr; 32(1):25. PubMed ID: 23631819
[TBL] [Abstract][Full Text] [Related]
38. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
[TBL] [Abstract][Full Text] [Related]
39. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
40. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
